MERZEE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MERZEE (MERZEE).
MERZEE (benzphetamine) is a sympathomimetic amine that stimulates the release of norepinephrine and dopamine from nerve terminals in the hypothalamus, leading to appetite suppression and increased energy expenditure.
| Metabolism | Primarily hepatic via N-demethylation and other oxidative pathways; metabolites include amphetamine and methamphetamine. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 65% of the administered dose; biliary/fecal elimination accounts for about 25%, with the remainder as metabolites. |
| Half-life | Terminal elimination half-life is 18-24 hours in healthy adults; prolonged in renal impairment (up to 60 hours in severe impairment). |
| Protein binding | 98% bound to serum albumin. |
| Volume of Distribution | 0.15 L/kg, indicating limited extravascular distribution (primarily confined to plasma and interstitial fluid). |
| Bioavailability | Oral bioavailability: 45-55% (first-pass metabolism). Not applicable for intravenous route. |
| Onset of Action | Oral administration: 2-4 hours; intravenous: 5-15 minutes. |
| Duration of Action | Oral: 12-24 hours; intravenous: 6-12 hours. Clinical effects may persist beyond dosing interval due to prolonged half-life. |
300 mg orally twice daily, increased to 300 mg three times daily as tolerated. Maximum 900 mg/day.
| Dosage form | CAPSULE |
| Renal impairment | GFR 30-89 mL/min: 300 mg twice daily; GFR <30 mL/min or on hemodialysis: 300 mg once daily. |
| Liver impairment | Child-Pugh Class A: no adjustment; Class B: 300 mg twice daily; Class C: not recommended. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | Consider lower initial dose (300 mg twice daily) due to age-related renal impairment; monitor for cognitive effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MERZEE (MERZEE).
| Breastfeeding | No human data on excretion in breast milk; M/P ratio unknown. Risk to infant cannot be excluded. Use caution, considering importance of drug to mother. |
| Teratogenic Risk | Insufficient human data; animal studies not available. Risk cannot be excluded. First trimester: potential for teratogenicity unknown; avoid if possible. Second and third trimesters: no specific risk identified but limited data. |
| Fetal Monitoring |
■ FDA Black Box Warning
MERZEE has a high potential for abuse and dependence. Use in patients with a history of drug abuse or alcoholism is not recommended. Administration for extended periods may lead to drug dependence and must be avoided.
| Serious Effects |
Hypersensitivity to benzphetamine or other sympathomimetics; advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; glaucoma; agitated states; history of drug abuse; during or within 14 days of MAOI use; pregnancy; lactation.
| Precautions | Risk of abuse and dependence; monitor for signs of abuse. Use with caution in patients with hypertension, hyperthyroidism, glaucoma, or anxiety states. Discontinue if tolerance develops. May impair ability to drive or operate machinery. Do not use with MAOIs or within 14 days of their discontinuation. |
Loading safety data…
| Monitor maternal renal function, liver function, and blood counts throughout pregnancy. Fetal ultrasound for growth and anatomy if exposure occurs during first trimester. |
| Fertility Effects | No human data on fertility effects. In animal studies, no impairment of fertility observed. |